News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma’s 2019 annual report published

March 30, 2020

PledPharma AB today announced that the Annual Report for 2019 now is available at the company’s website, www.pledpharma.se.

A printed version can be ordered through [email protected] or +468 -679 72 10.

Contacts

Nicklas Westerholm, CEO, phone: +46 73 354 20 62
[email protected]

Yilmaz Mahshid, CFO, phone: +46 72 231 68 00
[email protected]

About Us

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A phase III program is ongoing. The drug candidate Aladote® is being developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see http://www.pledpharma.com/

Attachments

PledPharma’s 2019 annual report published

«
»

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]